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INTRODUCTION
The development of new methods in
trauma and reconstructive surgery has created
new problems. Large traumatic bone defects
can be covered by soft tissues but reconstruc-
tion of the bone itself may be difficult. The
use of autogenous bone has remained the
golden standard in restoring bone defects, but
it is not always possible to obtain enough
bone. The patient may have undergone previ-
ous bone grafting procedures and thus have
poor donorsites or the amount of bone needed
may exceed that available. In addition, har-
vesting is always a secondary operation and
implies a certain amount of morbidity (Ban-
wart et al. 1995).
To avoid these problems, allograft bone
can be stored in bone banks for later use. Un-
fortunately this does not solve all the prob-
lems, as there is always a risk of being trans-
mitted by viruses or bacteria, when allograft
bone is used (Khan et al. 1998). Moreover,
the immunogenic responses may impair the
results (Aho et al. 1998).
Biomaterials may provide a solution to
these problems. An ideal bone substitute
should be tolerated by the host tissue without
any adverse reaction; it should promote bone
formation, have appropriate mechanical
strength, be malleable and resorb after it has
fullfilled its function. Porous calcium ceramics
have proved to be biocompatible bone substi-
tutes. The material most investigated in this
group is hydroxyapatite (HA). It can be
manufactured from natural reef building coral
skeleton by a hydrothermal exchange reaction,
where the trabecular, bone imitating structure
of the coral remains unchanged and the cal-
cium carbonate (CC) skeleton is converted to
calcium phosphate, the main inorganic salt of
bone (Roy and Linnehan 1974).
The original coral skeleton, consisting of
CC, can also serve as bone substitute. The
main difference between these structurally
identical materials is that biodegradation takes
place much more slowly with HA than with
CC. Biodegradation should not occur before
the implant has filled with bone. Very short
resorption times, even a few weeks, have been
reported for CC (Guillemin et al. 1989). This
accentuates the importance of fast bone in-
growth into the implant.
However, both HA and CC lack the ca-
pacity to induce bone growth. Adding bone
marrow to porous calcium ceramics induces
bone formation, even in extraosseal sites
(Okumura et al. 1991; Ohgushi et al. 1992).
This would make it possible to prefabricate
implants, e.g. inside muscle tissue and to
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transfer a composite muscle-ceramic-implant
as a vascularized graft to the defect area.
Another way to induce bone growth into
porous ceramics is to add growth factors to
the implant. Transforming growth factor beta
(TGF-ß) is an important regulator of bone de-
velopment, induction, repair and remodelling.
Not only does it have strong mitogenic activ-
ity on osteoblasts but it also enhances bone
matrix collagen production (Robey et al.
1987).
In 1991, Beck and coworkers showed in
rabbits that a single application of TGF-ß1
leads to new bone formation (Beck et al.
1991). Since then many different materials,
natural coral among them, have been investi-
gated for the delivery of TGF-ß to bone (Ar-
naud et al. 1994). Recently a preliminary
clinical report was published on the use of
TGF-ß in humans (Arnaud et al. 1998). Al-
though the results are promising, they must be
interpreted with caution due to the complex
effects of TGF-ß.
A bone implant with osteoinductive ca-
pacity would solve many of the problems as-
sociated with bone grafting. This study was
designed to investigate the properties of natu-
ral coral and hydroxyapatite to serve as bone
substitutes in a clinical human study and in
animal experiments. Bone ingrowth into the
implant was induced by bone marrow or by
TGF-ß.
Review of the Literature
___________________________________________________________________________
9
REVIEW OF THE LITERATURE
Structure of bone
Bone consists of a collagenous framework
upon which calcium salts are deposited
mainly as hydroxyapatite. The mature bone is
lamellar, its collagenous fibres building regular
patterns. In the cancellous bone the collagen
bundles lie parallel to the long axis of the tra-
becula and in the compact (cortical) bone the
fibres are disposed in concentric rings around
the vascular spaces.
Bone can also be considered as consisting
of cells and extracellular matrix, with 35% of
the matrix being composed of organic and 65%
of inorganic ones (Martin et al. 1988). The
inorganic part is formed of calcium salts and
the organic componenents of collagen and
noncollagenous proteins. The noncollagenous
proteins form 10% of the organic material.
They modulate matrix organization, bind cal-
cium and, like the bone growth factors, regu-
late bone formation and resorption (Sandberg
1991).
Bone healing
    Bone healing has been studied at length in
enchondral, tubular bones but much is still to
be learned of the healing mechanisms of in-
tramembranous bone, i.e. bone formed with-
out the cartilage phase. Such bone is found
mainly in the cranio-facial area.
In tubular bone trauma, osteoprogenitor
cells are recruited to the trauma site and are
differentiated to bone forming cells. Multipo-
tential cells from bone marrow and primitive
fibroblasts from adjacent soft tissues may also
be recruited. Biochemical, mechanical and bio-
physical factors are involved in this process,
in which periosteal cells are activated for the
repair process and the multipotential stem
cells and prefibroblasts are induced to differ-
entiate into osteoblasts.
The bone forming cells need a template to
attain the proper three-dimensional structure.
This is formed by the collagen network on
which the hydroxyapatite crystals are depos-
ited by the osteoblasts. This phenomenon,
called osteoconduction, helps to bridge large
segmental defects (Cornell and Lane 1992).
Fracture repair proceeds in three physio-
logically and histologically characteristic but
overlapping phases: 1) acute inflammation, 2)
reparation and 3) adaptation (Urist and John-
son 1941; Sevitt 1981). Different tissue types
are represented in the sequence: haematoma,
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granulation tissue, fibrous tissue, cartilage and
bone.
In the acute inflammation phase the haema-
toma forms, bone necrosis occurs and cell
death releases byproducts into the fracture
site. Inflammation begins within 48 hours and
lasts untill cartilage and bone appear. The in-
flammation activates the cellular mechanisms
necessary for the repair (Sevitt 1981).
In the reparative phase the fracture gap be-
comes highly cellular, vascularizes and forms
soft callus. Osteoblasti and chondroblasts be-
gin to appear in the fracture gap and to replace
the fibrovascular stroma (McKibbin 1978).
The soft callus is converted by enchondral
ossification to woven bone, where the collagen
fibres are randomly oriented. Ossification can,
however, happen without previous cartilage
formation.
The last phase is adaptation (modelling and
remodelling), starting early in the reparative
phase (Sevitt 1981). The woven bone is trans-
formed to lamellar bone with organized colla-
gen matrix. During this process the bone
shape is restored and the medullary canal is
reconstructed. This process, which may take
from months to years appears to be governed
by Wolff's law (Wolff 1892).
Bone grafting
History
Various materials, from gold to allografts
have been used to fill bony defects (Habal and
Reddi 1994). Despite the range of materials
available today, the standard procedure for the
repair of bony defects is still autogenous bone
grafting.
Even if autogenous bone grafts had been
used before, Leopold Ollier was the first to
study bone transplantation systemically
(Ollier 1858). He also pointed out the differ-
ence between auto-, allo- and xenografts. In
1914 Phemister described clinically the healing
of autogenous bone grafts and stressed the
importance of vascularization, the various tis-
sue components involved in bone healing and
creeping substitution (schleichender Ersatz)
(Phemister 1914). After them numerous in-
vestigators contributed to the research into
bone grafting, in particular after World War II,
when there were a great number of victims
with severe bone defects, especially in the
craniofacial area.
Autografts
The autogenous bone graft has several ad-
vantages over allo- or xenografts. It has greater
osteogenic capacity and it is biocompatible.
Review of the Literature
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As the autograft resorbs, revascularization
recruits mesenchymal-type cells, which dif-
ferentiate into osteogenic, chondrogenic or
other cell lines (Brown and Cruess 1982).
The high osteogenic potential of cancel-
lous bone derives from the bone marrow it
contains, and the marrow part as such can be
used to induce bone growth into different po-
rous materials (Nade et al. 1983).
The cancellous graft is mouldable and resis-
tant to infection; it vascularizes fast and can
be obtained quite easily, usually as “chips”
from the iliac crest (Burwell 1966). Unfortu-
nately the amount of cancellous bone is lim-
ited. Moreover, it cannot be used in stress
bearing areas, and the harvesting causes mor-
bidity, such as pain, haematoma, infection and
nerve injury (Banwart et al. 1995) or even iliac
hernia and ureteral injury (Challis et al. 1975;
Escalas and DeWald 1977). The major com-
plication rate amounts to 8.6% and the minor
complication rate to an additional 20.6%
(Younger and Chapman 1989).
Cortical (compact) bone is used when
mechanical support is needed. Common donor
sites used to be fibula, ribs and iliac crest. Un-
fortunately the biological properties of com-
pact bone are poorer than those of cancellous
bone, and the more compact the transplant the
slower the vascular invasion. The bone grafts
are replaced by local tissue through “creeping
substitution”, in which the graft acts as a scaf-
fold for growing fibrovascular tissue (Phemis-
ter 1914). Compact bone is probably never
fully replaced or invaded by the graft site tis-
sue; the outcome is therefore inferior integra-
tion and infections. It also has the tendency to
resorb, making it a unreliable material (Bur-
chardt 1983; Banwart et al. 1995).
Intramembranous grafts have been consid-
ered to resist resorption better than enchon-
dral grafts and their biological behaviour seems
to be different. Cortical (and cortico-
cancellous) grafts harvested from the calvaria
(skull) are commonly used in craniofacial sur-
gery (Tessier 1982).
The cortico-cancellous graft offers sta-
bility and osteogenic capacity. It can be used
in weight-loaded areas, often in spinal fusions
or in mandibular reconstructions. Vasculariza-
tion is, however slow and large defects cannot
be reconstructed due to the same complica-
tions as with cortical grafts.
Microvascular grafts have helped to over-
come some of the drawbacks associated with
the reconstruction of large defects. Large cor-
tico-cancellous grafts can be harvested with
their nutricient vascular pedicle, allowing the
vessels to be anastomosed to suitable artery
and vein in the recipient site. The healing
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takes place in the interface of the graft and
recipient bone as in a normal bone fracture
situation (Weiland et al. 1984). The donor site
complications may, however be more severe,
because the grafts used tend to be very large.
The periosteum contains osteoprogenitor
cells and can as such or as an osteo-periosteal
graft be used to enhance bone formation (Rit-
silä et al. 1976). This method has not gained
much popularity though.
Allografts
The known limitations of autografting, e.g.
secondary operation, limited availability of
bone and operation morbidity, have encour-
aged the search for other options. The natural
choice is allograft bone, human bone, usually
harvested from a dead person or obtained in a
hip fracture operation. The basic concept un-
derlying allograft bone use was established in
the early 1900s, when Baschirzev and Petrov
showed that most of the cell components in
the graft die after transplantation and that
bone regeneration starts from the host bed
(Baschirzev and Petrov 1912).
Allografts demonstrate a lower osteogenic
capacity, higher resorption rate and larger im-
munogenic response and, finally, less revas-
cularization of the graft than autografts (Chase
and Herndon 1955; Friedlaender et al. 1978).
Despite of these drawbacks, allograft bone
offers a useful adjunct to the range of bone
graft materials. Bone can be minced and mixed
with autogenous grafts in spinal fusions or hip
prosthesis operations (Burwell 1966). Al-
lograft bone can even be used for large grafts
comprising whole joints in tumour surgery.
The results, however, are somewhat contra-
dictory (Aho et al. 1998).
To maintain the availability of allograft
bone, a well-organized bone bank is needed
(Tomford et al. 1987). The possibility of
transmitting viruses or bacteria may limit the
use of allografts (Buck and Malinin 1994;
Khan et al. 1998).
Xenografts
The xenogenic bone graft, that is, a graft
made with bone from another species, pre-
sents similar problems to the allograft. It elic-
its an acute antigenic response with a high
failure rate. Partial deproteination and defat-
ting have been demonstrated to decrease the
antigenic response (Kiel bone) but at the cost
of the osteoinductive capacity. Xenografts are
indeed rarely used (Heiple et al. 1967).
Demineralized bone
Demineralized (decalcified) bone was first
studied in the late 19th century, when it was
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mainly used for filling cavities in osteomye-
litis operations (Senn 1889). It is manufac-
tured in a process whereby first the bone mar-
row is removed, then the bone is defatted and
finally the mineral contents are decalcified
with hydrogen chloride, leaving the collagen
matrix intact. Demineralized bone can be used
in powder form, in chips or in corticocancel-
lous blocks. Urist and coworkers noted the
osteoinductive capacity of demineralized
bone, and later attributed it to the influence of
morphogenetic protein (Urist and McLean
1941). Clinically demineralized bone has been
used primarily for craniomaxillofacial recon-
structions (Mulliken et al. 1981).
Mechanical properties of bone
Mature bone can be divided into cancellous
(trabecular) or compact bone, depending of
the degree of bone porosity. Compact bone
has a porosity of 5-30% and cancellous bone
of approximately 30-90%, which is the pro-
portion of the volume occupied by non-
mineralized tissue (Carter and Hayes 1977).
The diaphyses of long (tubular) bones are
composed mainly of compact bone whereas
the epiphyses and methaphyses consist of
cancellous bone that is continuous with the
inner surface of the cortical shell and exists as
a three-dimensional, sponge-like lattice com-
posed of plates and columns of bone. The tra-
beculae divide the interior volume of bone into
intercommunicating pores of different dimen-
sions. The composition and true densities of
compact and trabecular bone are thought to be
similar (Galante et al. 1970) as are the micro-
scopic material properties (McElhaney et al.
1970).
A key requirement in bone is compressive
strenght, and the most important factor in
compressive strength is the degree of miner-
alization. Loss of mineralization results in in-
creased risk of fracture (Wright and Hayes
1977). A collagen and hydoxyapatite com-
posite is advantageous from a mechanical
standpoint. Mineralized tissue can be consid-
ered as a a porous, two-phase composite con-
sisting of hydroxyapatite crystals embedded
in collagen matrix (Lees and Davidson 1977).
Increasing collagen intermolecular cross-
linking is associated with increasing minerali-
zation. The resulting composite structure is
much stronger and stiffer due not only to the
higher mineral content but also to the stiffen-
ing of the collagen matrix caused by the greater
cross-link density (Carter and Spengler 1978;
Mammone and Hudson 1993). It has been
suggested that the longitudinal strength and
stiffness of mineralized bone tissue are ap-
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mate failure (Mammone and Hudson 1993).
The elastic compressive modulus is the
slope of the load strain-curve in the most lin-
ear portion. Called Young´s modulus when
tension or compression are studied (Carter
and Spengler 1978), it reflects the stiffness of
bone.
The compressive strength of cortical bone
varies, being in humans around 200 MPa
(megapascals) for the femur; the elastic com-
pressive modulus is around 17 GPa (Reilly et
al. 1974; Reilly and Burstein 1975). Cancel-
lous bone is much weaker and the results ob-
tained have varied, depending on the location
of the bone (Goldstein 1987). Compressive
strengths of 0.15-27 MPa and elastic modulus
from 50 to 350 MPa have been reported for
cancellous bone (Table 1) (Schoenfeld et al.
1974; Carter and Hayes 1977; Manninen
1993).
Biomaterials
A biomaterial can be defined as “a material
intended to interface with biological systems
to evaluate, treat, augment, or replace any tis-
sue, organ, or function of the body” (Williams
et al. 1992). There are three classes of bioma-
terial: metals, polymers and ceramics. The
following looks briefly at some of the bioma-
terials used in clinical practice.
Metals
The main metals in clinical use are tita-
nium, vitallium, aluminium and stainless steel,
all of them inert and biocompatible (Mofid et
al. 1997). Metal implants are used for load
bearing purposes such as joint prostheses, and
screws and plates. They may undergo corro-
sion over time due to galvanic corrosion pro-
duced by two different types of metal. Fret-
ting corrosion may occur when the oxide film
on the metal is damaged by, say, a screw in a
plate hole (Gosain and Persing 1999).
The integration of metal prostheses to the
host bone can been promoted by coating them
with a bioactive ceramic such as hydroxyapa-
tite. Coating with plasma-sprayed apatite
leads to the formation of a strong bond be-
tween bone and metal implant (Geesink et al.
1988). This is particularly advantageous in
hip arthroplasty, where implants have a ten-
dency to detach with time.
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Polymers
Polymers comprise a large group of materi-
als of heterogenous origin. They are composed
of the macromolecules that are typically
formed by the bonding of one or a small num-
ber of types of subunits repeated along the
length of the polymer (Gosain and Persing
1999). A polymer widely used in traumatic
skull defects is methyl methacrylate. It is esy
to mould, cheap and nonresorbable and is even
stronger than calvarial bone. The infection rate
is considered to be comparable to that in bone
grafting procedures but its use is not recom-
mended for patients who previously had in-
fections in the cranioplasty site. The use of
methyl methacrylate requires good quality of
the overlying soft tissues (Manson et al.
1986).
Polyhydroxyethylmethacrylate with cal-
cium hydroxide coating (Hard Tissue Re-
placement, HTR®, Walter Lorenz Surgical,
Inc., U.S.A), is another popular polymer
composite. It is a nonabsorbable porous mate-
rial allowing tissue ingrowth into pores of 150
to 350µm. It can be prefabricated in custom
shapes and is mainly used in facial augmenta-
tions (Guyuron 1990).
Porous high-density polyethylene (Med-
por®, Porex Surgical, Inc., U.S.A.) is used in
facial augmentation surgery, in ear and orbital
reconstruction and to fill empty eyeball sock-
ets after enucleation or evisceration. The im-
plants are fixed to bone or soft tissue by fi-
brous tissue ingrowth. The material is not re-
sorbable, which is an advantage in augmenta-
tion surgery. The complication rate does not
seem to differ from that of bone graft proce-
dures. Among the disadvantages of polyethyl-
ene are its rigidity and the difficulty of con-
touring it to the surface of complex skeletal
structures (Guyuron 1990; Frodel and Lee
1998). Another polymer material is a syn-
thetic porous composite of polyethylene
polymer and aluminium (Proplast®). Although
it is light, porous, resilient, malleable and easy
to shape the material is currently little used
due to the high complication rate associated
with its application in recent yeas (Whear et
al. 1993).
Polyglycolide and polylactide are hard
synthetic crystalline polymers used as fixa-
tion material in orthopedic and craniofacial
surgery. In living tissue they degrade to gly-
colide and lactide mainly by hydrolysis. Their
unique mechanical properties are such that
they can be used for manufacturing screws,
pins and plates that absorb with time (Rok-
kanen 1998), thus eliminating the need for a
secondary operation of removing the fixation
material. In recent years the possibility of
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polyglycolide and polylactide acting as deliv-
ery material for growth factors has been inves-
tigated (Gombotz et al. 1994).
Ceramics
Ceramics consist of crystalline metallic
oxides, carbides, nitrides and borides fused by
the high temperature process known as sin-
tering. They are brittle, have low electrical and
heat conductivity and elicit very little tissue
reaction (Mears and Rothwell 1979). Differ-
ent glass ceramics are typical representatives
of this group of biomaterials. In the 1970s,
certain glass compositions were found to be
able to bond chemically to bone, a property
called bioactivity. The first bioactive glass,
Bioglass®, was composed of SiO2, Na2O, CaO
and PO5. Bioactive glasses are manufactured
by conventional glass manufacturing methods
and even minor changes in their composition
change the character of the bone-material
bonding and resorption (Hench et al. 1975).
Granular and solid forms of bioactive glasses
have been used clinically to reconstruct orbital
walls and facial bone defects and to obliterate
frontal sinuses. Bioactive glasses are osteo-
compatible and the infection rate is low. The
resorption rate may, however, be too high and
the migration of granules can cause problems
(Suominen and Kinnunen 1996).
Another important group of ceramics
comprises materials deriving from calcium.
Such ceramics are composed of calcium sul-
phate, phosphate and carbonate derivates and
their mixtures in dense, porous and granular
forms. The following sections examine these
materials in greater detail.
Calcium ceramics
Calcium sulphate
Plaster of Paris (calcium sulphate) was one
of the first materials to serve as bone substi-
tute. In 1892, Dreesman used it to fill bony
defects in eight patients with nine defect sites.
Six defects healed well and three remained un-
healed (Dreesman 1892). Since then calcium
sulphate has proved to be biocompatible and
adsorbable but not osteoconductive. Resorp-
tion occurs in weeks and may be too fast for
the bone formation process (Calhoun et al.
1967). This, together with its poor mechanical
properties, has limited the use of calcium sul-
phate as bone substitute.
Fast resorption may, however, be an ad-
vantage. In 1928, plaster of Paris was investi-
gated by Petrova as a delivery material for an-
tiseptics, and in the 1950s cylinders contain-
ing penicillin and sulphonamide were exam-
ined clinically (Peltier 1961). Recently the
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properties of calcium sulphate were suggested
to be suitable for a carrier of bone morphoge-
netic protein in a mouse model (Yamazaki et
al. 1988).
Calcium phosphate
Calcium phosphate biomaterials are poly-
crystalline ceramics deriving from individual
crystals of a highly oxidized substance that
have been fused together (Jarcho 1981). The
two most important are tricalcium phosphate
Ca3(PO4)2, or ß-whitlockite, and hydroxyapa-
tite Ca10(PO4)6(OH)2. Both materials are
known to be biocompatible and osteoconduc-
tive and to bond directly to bone. The main
difference between these two materials is that
tricalcium phosphate (TCP) degrades much
faster than HA (Jarcho 1981; Shimazaki and
Mooney 1985). The chemical structure of cal-
cium ceramics resembles that of bone. Hy-
droxyapatite is the main inorganic salt of bone
and the synthetic form has been shown to be
chemically and crystallographically similar,
but not identical, to naturally occurring HA
(LeGeros et al. 1988).
HA is the most studied calcium phosphate
material with clinical experience of its use go-
ing back to the 1970s (Hulbert et al. 1970).
Offering better integration to bone, porous
HA has now replaced the dense form. When
HA has been placed into bony defects, bone
growth into pores has ranged from 18% to
74% (new bone area compared to total im-
plant area) (Holmes et al. 1988; Martin et al.
1993). The entire porous space of the implant
is probably never completely filled with bone
(Rosen and McFarland 1990).
Porous HA can be manufactured in several
ways. Homogenizing calcium phosphate
powder with appropriately sized naphthalene
particles results in macroporous material after
the naphtalen has been removed. The final
form is achieved after sintering at high tem-
peratures (1100-1300°C). Another method
relies on the decomposition of hydrogen per-
oxide to generate a pore-filled structure.
The porous structure achieved in these
methods is not, however,  consistent. To
avoid this problem, a completely different
approach was developed in the early 1970s as
a joint investigation by the Materials Research
Laboratory at The Pennsylvania State Univer-
sity and the Orthopaedic Research Laboratory
of the Upstate Medical Center at Syracuse,
both in the U.S.A.
The idea is based on the finding that the
structure of certain reef-building coral species
resembles osteon evacuated bone (Holmes
1979). The coral pore size is consistent and
varies very little (Figure 2). A pore size of
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1990; Byrd et al. 1993; Kamegaya et al.
1994). Recently a hydroxyapatite cement was
developed for cranial defects. It is in paste
form and can be moulded into the desired
shape. The material integrates to the host
bone and is claimed to be replaced by bone, at
least to some extent (Costantino et al. 1992).
The high cost of the material has, however,
restricted its wider use clinically.
Porous HA is brittle and can be used only
in non-loading sites. Its compressive strength
is enhanced by bone ingrowth but it is only
comparable to that of cancellous bone (Martin
et al. 1993).
Slow resorption is advantageous in certain
clinical situations. If used as an onlay graft as
in alveolar ridge augmentation, degradation is
not desired. However, an ideal bone substitute
should be osteoconductive, osteoinductive,
biocompatible and easy to shape; it should
also biodegrade after it has been occupied with
new bone and be a reasonable price. Its me-
chanical properties should be comparable to
those of cortical bone. HA has many of these
qualities but it resorbs very slowly and is brit-
tle.
Calcium carbonate
Calcium carbonate (CaCO3) resembles hy-
droxyapatite in many respects. The material is
biocompatible and osteoconductive but, like
HA, has no osteoinductive properties
(Guillemin et al. 1987). The main difference to
HA is the resorption rate. Resorption seems
to be clinically unimportant with HA, but
animal experiments have shown resorption
rates of only a few weeks, when CC is used
(Guillemin et al. 1989).
Certain coral species form a structure that
resembles the matrix or bone. Each species
builds a structurally and geometrically typical
calcium carbonate skeleton. Choice of the ap-
propiate species therefore enables a desired
and constant implant structure to be achieved.
Coral reefs are formed by colonies of pol-
yps ranging in size from one millimetre to
several centimetres, depending on the species.
Coral polyps live in symbiosis with uni-
cellular algae, which photosynthesize com-
pounds essential to the polyps. The outer
layer of the polyp is capable of secreting a
substance that calcifies in the seawater milieu
and serves as matrix for the coral skeleton.
The coral polyp lives only in the upper part
of the skeleton, moving slowly upwards,
leaving an empty skeleton behind. Coral reefs
play an important role in maintaining the
equilibrium of carbon dioxide, which is ab-
sorbed from the seawater in the building proc-
ess.
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More than 2000 coral species have been
described from the intertropical area and, of
these, fourteen Scleractinian corals have been
studied as possible bone substitutes.The fol-
lowing genera have already been used as bone
grafts: Pocillopora, Acropora, Montipora,
Porites, Goniopora, Fungia, Polyphyllia,
Favites, Acanthastrea, Lobophyllia and
Turbinaria (Bouchon et al. 1995). The most
promising is Porites astreoides, which forms
massive colonies and is common throughout
the Caribbean area, including the Bahamas,
Bermuda and Brazil. The porosity of the
skeleton is around 50% and the mean size of
the pore is 150µm, the pores interconnecting
with each other.
The harvested coral is purified physically
and chemically and the final implant material
contains no proteins and less than 0.1% amino
acids. The manufacturer of the commerciably
available coral implant (Biocoral®) guarantees
the following chemical composition of the
product:
calcium carbonate >97%
trace elements 0.5-1%
magnesium 0.05-0.2%
sodium <1%
potassium <0.03%
phosphorus <0.05%
water <0.5%
Experimental studies on CC started in the
early 1970s. Chiroff and coworkers placed CC
in cancellous defects in dogs for 8 weeks and
found that the material was biocompatible and
that new bone could fill the pores. Some im-
plants were left for 1 year and were observed
to be almost completely resorbed (Chiroff et
al. 1975). The favourable results were con-
firmed when other animals, e.g. monkeys
(Souyris et al. 1984) and sheep and pigs
(Guillemin et al. 1989), were used.
The first clinical reports were published in
France by the Institut de Recherches Or-
thopédiques, Université René-Descartes Paris
V in 1980 (Patel et al. 1980). Since then CC
has been used clinically in maxillofacial sur-
gery to correct periodontal defects (Issahakian
and Ouhayoun 1989; Mora and Ouhayoun
1995) and to fill and reconstruct bony defects
in cranial surgery (Roux et al. 1988; Mercier et
al. 1996; Soost et al. 1998). The craniofacial
bones can be augmented by the granular form
of CC (Marchac and Sandor 1994). In ortho-
paedic surgery CC has been used as a filler in
tibial osteotomies (Kenesi et al. 1997), in bone
tumour surgery (Rouvillain et al. 1997) and in
lower limb metaphyseal fractures to support
articular surfaces (de Peretti et al. 1996). The
possibly most appropriate indication at the
moment is spinal fusion, where CC can be
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used to diminish the amount of bone grafts in
conjunction with autogenous bone (Pouliquen
et al. 1989; Kehr et al. 1995).
Little is known about bone ingrowth into
the CC implants. Bone and fibrous tissue do
grow into the pores but exact information is
scarce. This may be due to the difficulty of
measuring the already partially resorbed im-
plant. The same difficulty applies to meas-
urements of the mechanical properties, which,
according to the manufacturer, are better than
in cancellous bone.
Very little exact information exists also on
the resorption time of CC. It seems to depend
on the animal species used. When the implant
was placed in the cortex of the femur in pigs,
64% of the CC blocks were resorbed after 1
month, whereas in sheep the figure was 93%
(Guillemin et al. 1989). The granular form has
been observed to resorb completely at 24
weeks in a connective tissue site in pigs but,
in humans, the same material placed in subcu-
tis can still be found after several years (Mar-
chac and Sandor 1994; Naaman et al. 1994).
Roux and coworkers reported almost com-
plete resorption after 1 year in 50% of cases
when coral was used to fill craniotomy bur-
rholes in humans (Roux et al. 1988). Larger
blocks used in humans have still been x-ray
positive after 4 years (de Peretti et al. 1996).
Coral resorption is most active in the bone-
implant contact areas and proceeds centripe-
tally (Braye et al. 1996). Carbonic anhydrase,
an enzyme abundant in osteoclasts, plays a
key role in the resorption process. Locally it
lowers the pH at the osteoclast-implant inter-
face, dissolving the CC matrix (Chétail and
Fournié 1969; Gay and Mueller 1974; Guille-
min et al. 1981. Resorption can be halted by
the administration of the diuretic acetazola-
mide, a known inhibitor of carbonic anhydrase
(Guillemin et al. 1981). Moreover, according
to Fricain and coworkers, data suggest that
both fibroblasts and macrophages dissolve the
coral, and that one of the mechanisms is the
intracellular degradation in phagolysosomes
(Fricain et al. 1998, a). A prerequisite for the
process is direct contact between these cells
and the coral matrix (Fricain et al. 1998, b).
Induction of bone growth into cal-
cium ceramics
Enhancement of bone growth
Porous calcium ceramics are osteocompati-
ble (Jarcho 1981; Doherty et al. 1994) and
osteoconductive (Chiroff et al. 1975) but they
lack the capacity to induce new bone forma-
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tion from determined osteogenic precursor
cells, a quality known as osteoinduction.
Osteoinduction can be attained by har-
vesting bone marrow cells as such or in con-
junction with autogenous bone and placing
them at a site where bone formation is needed,
e.g. at bony defects caused by fracture or by
pseudoarthroses. Another way is to induce
bone growth by the members of the TGF-beta
superfamily, a group of growth factors that
make an important contribution to the bone
formation process.
Bone marrow
Back in 1869 Goujon observed heterotopic
(extraskeletal) bone formation after red bone
marrow transplantation. Bone marrow con-
tains osteogenic precursor cells, which are ca-
pable of differentiating into osteoblasts. When
marrow is placed in a heterotopic site (subcu-
tis, muscle), bone may derive from these cells,
from endosteal osteoblasts or from the host
cells at the site of grafting, induced to differen-
tiate by bone marrow (Burwell 1985). In 1971
it was found that autogenous marrow formed
bone in association with various materials and
that calcified matrix increased the ostegenic
capacity of the marrow (Newman and Boyne
1971). In 1980 Lindholm and Urist reported
enhanced bone formation in composite grafts
of bone matrix and bone marrow (Lindholm
and Urist 1980). A year earlier McDavid and
coworkers had placed tricalcium phosphate
pellets with autogenous bone marrow under
the skin of rats. At 4 weeks bone was evident
only in marrow-coated implants (McDavid et
al. 1979). Porous aluminate, calcium alumi-
nate, HA and TCP inserted together with mar-
row into the intermuscular space of rabbits
were observed to allow bone formation (Nade
et al. 1983).
Ohgushi and coworkers investigated po-
rous calcium phosphate (60% HA and 40%
TCP) blocks in a segmental rat-femur defect
experiment. The group treated with bone mar-
row showed significantly better osseous or
osteochondral union than did the control
group without marrow (Ohgushi et al. 1989).
Placing similarly treated implants into the
subcutaneous pouches of rats resulted in bone
ingrowth only into the implants treated with
bone marrow; after 1 months the proportions
of the pore area filled with bone for implanted
HA and TCP were 16.9% and 15.1%, respec-
tively. After 2 months the proportions were
34.3% and 30.9 % (Ohgushi et al. 1990).
Later, CC disks (genus Porites) were investi-
gated similarly and bone formation was ob-
served after 3 weeks. No histomorphomeric
analysis was, however, performed.
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Transforming growth factor-beta
The data above show that bone formation
can be induced into porous calcium implants
by bone marrow. The next step is to prefabri-
cate implants with already existing potential
for bone formation. Members of the trans-
forming growth factor-beta superfamily play
an important role in the bone formation proc-
ess and may offer a solution to the manufac-
ture of such bone substitutes.
TGF-ßs are a group of growth regulatory
peptides consisting of five isoforms (Roberts
et al. 1988). They form the TGF-ß superfa-
mily together with bone morphogenetic pro-
teins (BMPs) and the embryonical growth
factors inhibin, activin and the Müllerian sub-
stance (Massague 1990). The unifying prop-
erties of these peptides are their similarity in
structure and their ability to regulate devel-
opment and cellular differentiation.
The five TGF-ß isoforms are encoded by
closely related genes. Three of them, TGF-ß1,
ß2 and ß3, are found in mammalian bone,
which is the largest reservoir of TGF-ß the
concentration being 100 times as high as in
other tissues. TGF-ß1-3 are very similar in
their way of action and are here considered
together as TGF-ß.
Platelets are the most concentrated source
of TGF-ß although most cells can synthesize
it (Massague 1990). TGF-ß1 was first iso-
lated from human platelets (Assoian et al.
1983) and was later cloned from the human
complementary DNA library (recombinant
TGF-ß) (Derynck et al. 1985). The universal-
ity of its action is emphasized by the almost
identical amino acid sequence in various
mammalian and avian species (Massague
1990).
TGF-ß is a homodimeric protein of 25kDa.
It is found in the form of an inactive high mo-
lecular weight complex that is activated by an
acid environment, heat and enzymatic activ-
ity. Such an of environment is found close to
the osteoclast. Osteoclast activity could acti-
vate TGF-ß, which then activates the os-
teoblasts (Brown et al. 1990) with the highest
amount of TGF-ß receptors (Robey et al.
1987). This could be an important part of
bone remodelling.
TGF-ß is a major regulator of bone devel-
opment, induction, repair and remodelling. It
has strong mitogenic activity on osteoblasts
and it enhances bone matrix collagen produc-
tion (Robey et al. 1987). It also plays an im-
portant role in soft tissue repair, chronic in-
flammatory fibrotic disorders, autoimmune
diseases, and even in the repair of ischaemic
cardial injury (Roberts and Sporn 1993).
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In 1991 Beck and coworkers showed in
rabbits that a single application of TGF-ß
triggers a cascade of events leading to new
bone formation in the course of 49 days (Beck
et al. 1991). They used the critical size defect
(CSD) model (a defect large enough not to be
able to heal) (Schmitz and Hollinger 1986),
drilling a 12mm large hole into the parietal
bone and filling it with TGF-ß mixed with 3%
methylcellulose. Bone formation was minimal
in the control groups.
Since then very different materials have
been investigated for the delivery of TGF-ß to
bone, such as calcium sulphate implants and
polylactic-coglycolic acid devices (Gombotz
et al. 1994), gelatin sponge (Bosch et al.
1996), wax-like biodegradable polymer ce-
ramics (Schmitt et al. 1998), tricalcium phos-
phate coated titanium implants (Lind et al.
1996) and demineralized bone matrix
(McKinney and Hollinger 1996; Moxham et
al. 1996; Ripamonti et al. 1996). The results
have been encouraging, but limited bone for-
mation has also been reported (Bosch et al.
1996; Ripamonti et al. 1996; Wikesjö et al.
1998).
Centrella and coworkers noted that the ef-
fect of TGF-ß on bone cell replication is
biphasic and depends on both the TGF-ß con-
centration and the cell density in monolayer
culture (Centrella et al. 1987). Dose depend-
ence becomes more complicated when TGF-ß
is released from different vehicles and when
different animal species are used. Doses of
between 0.4µg and 40µg have most commonly
been used with conflicting results (Lind et al.
1996; McKinney and Hollinger 1996). Ri-
pamonti and coworkers suggested that the
limited bone formation is the result of TGF-
ß's capacity to stimulate the proliferation of
only periosteal and endosteal cells rather than
to initiate bone cell differentiation, as does
bone morphogenetic protein (Ripamonti et al.
1996). They also noticed a synergism in the
function of TGF-ß and BMP in a heterotopic
baboon experiment and postulated that TGF-
ß might act as a chemotactic and mitogenic
factor for responding precursor cells for sub-
sequent induction by BMP (Ripamonti et al.
1997).
Coral has also been evaluated as a growth
factor carrier, mainly in granular form. Damien
and coworkers applied bone morphogenetic
like protein and basic fibroblast growth factor
(bFGF) to CC and noticed good ossicle forma-
tion only when BMP was present, whether
with or without bFGF. The implants were
placed into the subcutis of rat and they pos-
tulated that coral-collagen was a good carrier
vehicle for BMP and should be tested in a
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bony site (Damien et al. 1993). BMP and
coral granules were later evaluated in spinal
fusions in rabbit but solid fusions were ob-
tained only in BMP groups, not in controls
(Boden et al. 1997).
There are very few reports of TGF-ß in
association with CC. Arnaud and coworkers
tested 1µg of TGF-ß1 with coral granules and
fibrin glue in a CSD model in rabbits and ob-
tained significantly better bone formation with
this combination at 2 months than with TGF-
ß1 in methylcellulose or in fibrin glue alone
(Arnaud et al. 1994). Another investigation
showed only marginal bone growth stimula-
tion at 4 weeks in a canine periodontal defect
model with granular coral, hydroxyethyl
starch and 20µg of TGF-ß1. The authors pos-
tulated that the healing interval of 4 weeks
was too short or that the experimental model
itself diminished the effect of TGF-ß1
(Wikesjö et al. 1998).
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AIMS OF THE PRESENT STUDY
The experiments described here were designed to investigate the properties of natural coral and hy-
droxyapatite and their capacity to serve as bone substitutes. The specific aims were:
1. to examine the capacity of bone marrow (I) or TGF-ß1 (III) to induce bone ingrowth into
porous HA (I) and CC (I, III) implants;
2. to study the effect of tissue ingrowth on the mechanical properties of HA and CC implant
(II); and
3. to examine the resorption rate and pattern of coral implants when placed in extraosseal (I)
and in orthotopic (III, IV) sites and to establish the extent to which the implants were re-
placed by new bone.
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MATERIALS AND METHODS
The study comprises three animal experi-
ments on rats (I-III) and one prospective
study on humans (IV).
The study followed the principles of the
European Convention for the Protection of
Vertebrate Animals Used for Experimental
and Other Scientic Purposes and was ap-
proved by The Research Animal Commission
of Helsinki University Central Hospital and
by the Provincial Administrative Board (I-
III).
All patients enrolled in the study re-
sponded to the Informed Consent protocol
approved by our Institutional Committee on
Human Research and stated that they found it
acceptable (IV).
Animals and patients
Experimental animals, anaesthesia and post-
operative follow-up (I-III)
The experiment was conducted on 113
Wistar rats ranging in weight from 250g to
650g. The numbers of implanted blocks at dif-
ferent follow-up periods are given in Table 2.
The animals were anaesthetized with an in-
traperitoneal injection of pentobarbital (50
mg/kg, Mebumat®, ORION, Finland) and
were given procaine penicillin (300 000 IU/kg,
Procapen®, ORION, Finland) intramuscularly
before the operation. Postoperatively no im-
mobilization was used. The rats were allowed
an ad libitum diet of rat chow and water and
inspected daily for general health.
Patients (IV)
The study group comprised 10 patients,
one female and nine male. Five of the patients
were unable to walk because of tetra- or
paraparesis. The median age was 37 (range 25-
79) years.
Another 10 patients, likewise one female
and nine male, acted as controls. Five patients
were para- or tetraplegic. The median age was
55 (range 17-78) years.
Implants
Natural coral (I-IV)
The coral implant material in all studies
was calcium carbonate, CaCO3 (Biocoral
®,
INOTEB, St. Gonnery, France), a porous
natural coral of the genus Porites. Its mean
porosity is 50% and pore size around 150µm,
all the pores interconnecting with each other.
99% of the original material consists of cal-
cium carbonate, the remaining 1% comprising
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organic materials, which are eliminated in the
purification process.
Hydroxyapatite (I-II)
The hydroxyapatite (Interpore 200®,
INTERPORE INTERNATIONAL, Irvine,
USA) was manufactured from natural coral
skeleton by a hydrothermal exchange reaction
in which the calcium carbonate skeleton is
converted to calcium phosphate. In this proc-
ess the trabecular structure of the coral re-
mains unchanged. The implants derive from
the same coral species, Porites, as the natural
coral implants used, and are structurally alike.
Transforming growth factor beta (III)
Lyophilized recombinant human trans-
forming growth factor beta1 was obtained
from Bristol-Myers Squibb Pharmaceutical
Research Institute (Seattle, WA, USA). The
specific bioactivity of the TGF-ß1 released
from the CC carrier was determined by a cell
growth inhibition assay (GIA). The assay
measured the capacity of active TGF-ß1, di-
luted from the lyophilized implants, to inhibit
the growth of mink lung epithelial cells in a
dose-dependent manner when added in differ-
ent concentrations (Ikeda et al. 1987).
Preparation of implants
Studies I-II
In studies I and II similarly shaped CC and
HA blocks were inserted. The HA blocks
were cut with a diamond saw longitudinally in
the main pore direction, taking anisotropy
into account. The implant size was 3x3x6mm
for both materials. The CC blocks were pre-
fabricated by the manufacturer.
The bone marrow obtained from the femur
was mixed with 1ml of saline and the implant
was immersed in the solution for 5 minutes
before insertion in to the muscle.
An implant of the same material without
bone marrow served as a control.
Study III
Four kinds of CC implant were prepared:
coral implants as such and implants with 1µg,
5µg and 25µg of TGF-ß1. Disks, 2mm thick
and with a mean weight of 0.78g, were cut
with a diamond saw from a 30mm long cylin-
der (Biocoral®, BIO-CTV 1-2). The TGF-ß1
was diluted to phosphate-buffered-saline
(PBS) in three different concentrations.
0.03ml of one of the three solutions was
added to an implant, resulting in disks con-
taining 1µg, 5µg or 25 µg of TGF-ß1. The im-
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and the wound was closed with running nylon
sutures in one layer.
Natural coral as filling material at iliac crest
(IV)
In the study group a 30x30mm bicortical
bone graft was harvested from the iliac crest.
In one patient the block was removed from
the posterior and in the others from the ante-
rior part of the crest. The bone graft was used
for spinal fusion in eight patients, for humeral
fracture correction in one and for recurrent
humeral dislocation surgery in one. The coral
implant was fitted to the defect with a soft
impaction mallet without any fixation. The
overlying soft tissues were sutured in layers.
A similar bone graft was harvested in the
control group but the defect was left empty.
A cervical fusion due to trauma was per-
formed in all patients.
Methods of analysis
Sampling and fixation techniques
The animals were killed with an overdose
of pentobarbital (I-III).
To prepare the samples for further proc-
essing in study I, the muscle around the im-
plant was dissected.
In study III the parietal bone was cut
around the defect area with a diamond saw
and the whole block, with or without the im-
plant, was harvested.
In study IV a cylinder-shaped biopsy was
taken perpendicular to the implant at the iliac
crest, without any imaging assistance, while
the patient was under local anaesthetic. The
cylinder measured 3 or 6 x 10-20mm.
All the samples, except those in study II,
were dehydrated in increasing concentrations
of ethyl alcohol-water solution and embedded
in methylmethacrylate.
In study II the implants were immersed in
saline after harvesting and a compression test
was performed within 24 hours.
Histology (I, III and IV)
5µm-thick sections were cut in the centre
of the implant or defect area, with microtome
(Polycut S, Reichert-Jung, Nussloch, Ger-
many) and stained with the Masson-Goldner
method (Goldner 1938) for histological and
histomorphometric analysis (Figure 5a-c).
The specimens were studied by ordinary
light microscopy. The quality of bone was
assessed and the number of osteoblasts, os-
teocytes and giant cells and the amount of fat
and bone marrow were evaluated on each
sample. Special interest was focused on the
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Testing was performed vertically towards the
smallest area of the specimen. Compressive
strength was calculated from the load-strain
curve by the ratio of the ultimate compressive
load to the cross-sectional area of the speci-
men. The elastic compressive modulus was
taken to be the slope of the load strain-curve
in the most linear portion (Figure 1). Alto-
gether 54 implanted blocks were tested. In
addition, implants of both materials in natural
form (dry) and after being immersed in saline
(wet) for 24h were measured. Five diaphyses
of rat femurs cut from the cortical part of the
bone were also tested (Table 2).
Statistics
The Kruskal-Wallis nonparametric test
was used for statistical analysis in study I and
p<0.05 was considered significant. Values
were given as means (±SEM).
As well as the Kruskal-Wallis test a multi-
ple comparison with the nonparametric ver-
sion of Tukey's test was performed when
more than two experiments were analysed
(II).
In study III the differences in the means of
the measured variables were compared with
one-way analysis of variance and Tukey's
Studentized Range Test. The values are given
as means (±SD), and P values smaller than
0.05 were considered statistically significant.
In study IV the density measurements were
tested by Friedman's two way analysis of
variance (ANOVA) by ranks and the Wil-
coxon signed-rank test.
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RESULTS
Study I
Histology
None of the control implants showed bone
formation. A giant cell reaction and invasion
of macrophages were observed in both materi-
als. Small foreign-body type granulomas could
be detected in some of the CC implants. No
acute inflammation was seen in any of the
specimens. The CC implant was successively
deformed, whereas the HA implants were un-
changed in size and form. Practically all the
pores in both control materials were filled
with fibrovascular tissue at 3 weeks.
Bone was formed in all implants with bone
marrow. At 3 weeks abundant osteoblastic
activity was seen directly on the surface of
the pores. Bone formation had proceeded so
far that scattered osteocytes and woven bone
could be detected (Figure 7a and b). In both
implants types numerous giant cells and
macrophages were seen but only in direct con-
tact with the foreign material, never adjacent
to new bone formation. Only scattered lym-
phocytes were present, and no acute inflam-
mation could be detected. The pores were al-
most completely filled with fibrovascular and
bone tissue.
At 6 weeks bone marrow, too, was pre-
sent, and both materials showed less os-
teoblastic activity than at 3 weeks. In some of
the CC specimens mature, lamellar bone were
also noted. In the CC specimens there were
fewer giant cells and macrophages than at 3-
weeks but in the HA specimens the number
was unchanged. Some fibrovascular stroma,
but no fat, could be seen in the pores in the
periphery of the blocks of both groups.
At 12 weeks bone marrow was still pre-
sent in both types of material. The amount of
mature bone had increased and there was less
osteoblastic activity. In the CC specimens
only a few giant cells or macrophages could be
seen. In contrast, giant cells and macrophages
were evident in the HA specimens in all areas
where bone did not line the implant material.
The CC implants were deformed and nearly
all the coral material not lined by bone had
been phagocytized. In CC blocks the inner-
most part of the implant was occupied by
bone marrow surrounded by mature bone, and
the implant resembled an ossicle (Figure 7c
and d).
In the HA implants bone marrow was still
present at 24 weeks, although fat cells had
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gradually invaded the pores and replaced the
marrow. There was some osteoblastic activ-
ity, but most of the bone tissue was already
quite mature and contained abundant osteo-
cytes. Some giant cells could still be detected.
The size and form of the implant were un-
changed (Figure 7e and f).
No cartilage was detected in any implant.
Bone formation did not show a centripetal
pattern; instead bone was scattered all over
the sample. New bone always appeared adja-
cent to the implant matrix.   
Figure 7. Bone formation in CC and HA implants with marrow (I)
a) CC at 3 weeks. Abundant osteoblastic activity (big arrow). Matrix (white) is partly phagocytized ( a r -
row), x200.
b) HA at 3 weeks. Giant cells and macrophages lying directly on matrix (arrow), x260.
c) CC at 12 weeks. Implant has lost shape and form, bone marrow occupies central part and is surrounded
by lamellar bone (dark) and matrix, x80.
d) Same specimen as in c: Osteoblastic activity and osteoid seam are still seen, x400.
e) HA at 24 weeks: Form and shape of matrix (grey) is preserved, bone (dark) invades entire implant,
x80.
f) Same specimen as in e: Fat gradually replaces bone marrow (arrow), x400.
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treated with marrow could still be tested but
the control blocks had deformed to such an
extent that they could no longer be measured.
All the HA blocks had preserved their shape,
even at 12 weeks.                  .
Compressive test   
Figure 9. Tissue ingrowth into implants with bone marrow (I). Relative amounts of matrix and
different tissue components and relative sizes of implants are presented for different follow-up peri-
ods. 100% is original total cross sectional area of implant.
Left side: coral implants, right side: hydroxyapatite implants.
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Compressive test
The test data are presented in Figure 10
and Tables 4 and 5. In the HA group with
bone marrow, compressive strength was sig-
nificantly higher at 3, 6 and 12 weeks than in
the wet blocks without any tissue ingrowth
(Figure 11a). The highest mean strength,
11.0MPa, was achieved at 12 weeks. The
compressive strength did not, however in-
crease significantly over time after 3 weeks in
either the marrow or the control groups. The
increase in strength in the control implants
was significant at 6 and 12 weeks when com-
pared with the wet blocks. The HA marrow
group showed higher strength values than did
the controls at 12 weeks but not at 3 or 6
weeks. There was no difference in the elastic
compressive modulus over time within the
HA with marrow or within control groups,
nor when the groups were compared with
each other.
The highest compressive strength in coral
blocks was measured in the dry group
(14.1MPa) after which the strength decreased,
in the marrow group to 2.3MPa at 3 weeks. A
slight, but non-significant, increase in com-
pressive strength was observed in the marrow
group at 6 weeks (4.0MPa).
The decrease in strength was highly signifi-
cant when the dry CC blocks were compared
with the 3-and-6 week specimens in the mar-
row group and also with the control implants.
The 3-week coral control blocks were the
weakest of all implants (0.9MPa). At 3 weeks
strength values were significantly
higher in the coral marrow group than in the
controls.
The elastic compressive modulus was
lower in both implanted coral groups at 3
weeks than the dry blocks
The compressive strength and modulus
values of dry coral were higher than those of
the dry HA blocks. The values of wet coral
were also higher than those of wet HA. The
five diaphyseos samples of the cortical rat
femur tested gave a mean compressive
strength of 116MPa.
Figure 11. Statistical significance of com-
pression strength testing of HA and CC implants
with marrow (II).
a) hydroxyapatite, b) coral. The arrow shows
the direction of the increase in strength.
*=p < 0.05, **=p < 0.01
Figure 10. Compressive strength of im-
plants (II).
Dry and wet implants are marked with       and
are the same for blocks with marrow and for
controls.
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Study III
Macroscopic observations
All the control coral blocks were clinically
mobile at removal in contrast to the treatment
groups, in which all implants, exept one, were
firmly fixed to the calvarium. The one implant
in the 8w/25µg group was partially unat-
tached.
Growth inhibition assay
The mink lung epithelial cell test showed
that the specific bioactivity of the TGF-ß1
released from the CC carrier was in active
form.
Histology
In the coral control samples, the structure
of the implants had already partly collapsed
at 3 weeks (Figure 12A). In the TGF-ß1-
treated implants, however, the shape and
structure were still well preserved at 8 weeks
(Figure 12B). In the non-treated samples,
abundant reactive cells consisting of both giant
cells and macrophages were noted in the pores
of the coral implant. Marked resorption
of the biomaterial, leading to break-down of
the structure, was also visible (Figure 12C). In
the implants treated with TGF-ß1 the number
of reactive cells was very low (Figure 12D).
The control implants were completely filled
with fibrous tissue ingrowth at 3 weeks
whereas in the samples treated with 5 or 25µg
of TGF-ß1, pores void of tissue could be ob-
served (Figure 12E).
Only scattered lymphocytes, and no neu-
trophilic leucocytes, were detected, as none of
the implants were infected.
The defect edge in the empty controls was
roundish, with only marginal new bone forma-
tion. In the treatment groups, new bone had
been produced mostly between te implant and
the calvarial bone and above and underneath
the defect edge and along the dura. Inside the
implant, bone was found only to a lesser ex-
tent (Figure. 12F). In some cases, abundant
osteoblasts and an osteoid rim could be seen
after 8 weeks. In more mature areas, the new
bone contained osteocytes and bone marrow
cells (Figure 12F). Cartilage was not found.
Histomorphometry
In none of the groups did the newly
formed bone bridge the defect, nor was there a
statistical difference in the diameter of the
hole. On the other hand, bone formation was
statistically more abundant in all the 8-week
treatment groups than it was in the empty or
coral controls. There was more bone in the
5µg and 25µg groups at 8 weeks than at 3
weeks (Figure 13). The implant-calvaria inter-
face showed more bone formation in the
8w/5µg group than in the coral controls and
the amount of fibrous tissue in all the TGF-ß1
implants at 8 weeks was also lower than in
the controls. The implant was statistically
smaller in the 8 week coral control group than
in the 8w/25µg group (Figure 14).
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Study IV
Macroscopic observations
The immediate postoperative recovery of
the donor sites was uneventful. All implants
were clinically tightly fixed at 1 year. In one
patient, pieces of the coral implant started to
extrude after 1.2 years and the remaining im-
plant was removed 1.7 years after the opera-
tion.
Radiographic findings
The implants showed up clearly in plain x-
rays in the early postoperative phase, but af-
ter 6 months the contours had become indis-
tinct and the exact boundaries of the blocks
were difficult to detect. The central part re-
mained more radio opaque, indicating that re-
sorption was proceeding centripetally (Figure
15A and B).
CT scans showed the implants more
clearly (Figure 15C-E). Although they had
become smaller over time, there was no sig-
nificant change in density, neither in the block
remaining nor when the immediate postopera-
tive density was compared with the final
measurements. Fragmentation was noted in
five patients; this most likely occurred
through the existing two burrholes (designed
for fixation) or through the hole caused by the
biopsy .
In the control patients, the donor site was
deformed, the remodelling of the bone making
Figure 14. Implant resorption in the
calvarial defects (III).
The * represents the statistically signifi-
cantly lower (p<0.05) resorption of 25µg
TGF-ß1 implant than in the 8-week coral
control.
Figure 13. Bone formation in the calvarial
defects (III)
Bone formation is given as the sum (±SD) of the
bone area of the three fields measured in study
III (Fig. 6A). The * symbol above the columns
shows the statistical difference (p<0.05) from
empty and coral controls.          stands for en-
hanced bone formation (p<0.05) from 3 to 8
weeks inside the same TGF-ß1 dose group.
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the defect edges rounder and flatter but never
filling the defect to its original shape.
Resorption
All implants resorbed to some extent, but
none completely (Table 6). Three blocks did not
change their resorption category from 1 year to
the end of the follow-up period. The iliac crest
did not regain its original form in any patient
during the follow-up.
?
Figure 15. Plain x-rays and CT
scans of two patients (IV). A and B
are from a different person than C-E.
The implant in CT scans C-E resorbed
the most rapidly of all blocks.
A) X-ray of coral block 3 months
postoperatively
B) The same block after 2.3 years.
The arrow points to the resorbed part
of the implant.
C) CT scan 2 months postoperatively.
The implant is integrated with bone.
D) At 1 year, the implant has frag-
mented; the arrow points to the
larger piece.
E) Only small fragments of coral re-
main after 2.1 years. The shape of
the iliac crest has not been restored.
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Histology
The histological findings are summarized in
Table 7. Three of the ten samples were excluded
from the histological study, as they contained
mature bone and bone marrow without any
signs of coral matrix. The x-rays and CT scans
showed that at least 50% of the implant still
remained in these samples, too, suggesting that
they had been taken from adjacent normal bone
and therefore did not represent the implant site.
Ingrowth of fibrous tissue was observed in
six of seven samples and in two of them bone
was also detected (Figure 16A and B). Only in
one sample was the coral matrix totally devoid
of tissue; this block resorbed the least of all im-
plants (Figure 16C).Giant cells and macro-
phages were present in areas with tissue in-
growth. These reactive cells were in direct con-
tact with the matrix, indicating their function in
the resorption process (Figure 16D). Scattered
lymphocytes were seen in a few samples, the
majority not containing any lymphocytes or
granulocytes at all.
One implant was infected at 1.2 years, 2
months after the biopsy (patient no. 7). The 1
year biopsy specimen was without leukocytes,
suggesting that the implant became infected af-
ter the sample was taken. This implant had to
be removed after 1.7 years. The matrix was well
preserved in the particles removed, and some
fibrous ingrowth and bone could be detected.
Abundant granulocytes, a sign of infection, were
also observed (Figure 16E and F).
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GENERAL DISCUSSION
Background
The porous structure of natural coral, ge-
nus Porites, was previously found to be simi-
lar to that of osteon evacuated cortical bone
(Holmes 1979) and to allow tissue ingrowth
(Hulbert et al. 1970; Chiroff et al. 1975). The
hydrothermal exchange reaction enabled the
calcium carbonate skeleton to be converted to
a calcium phosphate replica. Hydroxyapatite
(calcium phosphate) forms 85% of the inor-
ganic part of bone, and it was only natural to
develop implants that resemble bone tissue in
constitution and structure. HA has many good
qualities for a bone substitute but it resorbs
very little. The use of HA as bone substitute
has been widely documented since 1975 and
new applications are still being developed
(Costantino et al. 1992).
The coral skeleton is 99% calcium carbon-
ate and can also serve as bone substitute. CC
is resorbable but otherwise resembles HA.
Coral was chosen in the present investiga-
tion because of the promising reports pub-
lished. Until the early 1990s there was no ex-
perience of calcium carbonate as a bone sub-
stitute in Finland, whether in clinical or in ex-
perimental works.
Even though experiments on natural coral
as bone substitute started back in the 1970s
(Hulbert et al. 1970; Guillemin et al. 1981),
coral is still not a well known material. One
reason is that most reports of the earlier ex-
periments on coral were published in French.
Bone ingrowth
Bone marrow
When HA implants without bone marrow
have been placed in bone defects, bone in-
growth into HA has been variable. In orthog-
natic patients, Holmes an coworkers found
18% bone invasion (compared to total meas-
ured area) in a follow up time of 4.7 to 16.4
(mean 9.3) months in HA implants (Holmes
et al. 1988). Martin and coworkers placed HA
blocks in cortical defects of dog humerus and
radius. Bone ingrowth into pores increased
from 52% at 16 weeks to 74% at 1 year
(amount of bone relative to porous space). In
the cancellous site, bone ingrowth was 38% at
4 weeks, then fell to 17% at 1 year (Martin et
al. 1993). It would appear that the entire po-
rous space of HA is seldom completely filled
with bone (Rosen and McFarland 1990).
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Bone ingrowth into CC is more difficult to
measure because of resorption. CC loses its
internal porous structure very quickly, in our
study (I) after 6 weeks, and after that the
bone does not actually invade the pores but
replaces the matrix.
In studies III and IV we observed that
when CC implants are placed into bone de-
fects the amount of new bone without any
inducing factor is scarce. The coral controls in
calvarial defects (Figure 13) showed very little
bone formation (III) and no bone could be de-
tected in five of seven biopsies taken from the
iliac crest implants at one year (IV).
Adding bone marrow to porous calcium ce-
ramics induces membranous bone formation in
extraosseal sites. This has been shown with
tricalcium phosphate blocks implanted subcu-
taneously in rats (McDavid et al. 1979), with
HA blocks implanted intramuscularly in rab-
bits (Nade et al. 1983) and rats (Okumurai et
al. 1991; Ohgushi et al. 1992) and also with
CC implanted subcutaneously in rats (Oh-
gushi et al. 1992). In study I bone was formed
in all implants placed intramuscularly with
bone marrow but in none of the controls.
More bone was produced in CC than in HA
implants at 3 and 12 weeks, although at 12
weeks the CC blocks had been reduced to
40% of their original cross sectional size. The
absolute amount of bone did not increase sig-
nificantly within either group after 3 weeks,
but there was a trend of increasing bone for-
mation in HA implants at 24 weeks
(p=0.051), when the amount of bone was
about the same as in CC implants at 12 weeks
(14.4%/13.7%, Figure 8). As the two implants
are similar in structure, the difference in
chemical constitution and in the resorption
process of the CC matrix itself may affect
bone formation.
Ohgushi and coworkers implanted CC and
HA disks with bone marrow into subcutane-
ous pouches in rats. At 4 weeks bone occu-
pied 19.1% (HA) and 22.0% (CC) of the po-
rous area (Ohgushi et al. 1992). Our results (I)
for intramuscular sites at 3 weeks were 13.5%
(HA) and 20.1% (CC). Ohgushi found bone
only in blocks immersed with bone marrow,
not in those without it. This is in accordance
with our findings here and also with previous
reports where porous ceramics were used
with bone marrow in extra osseal sites in rats
(McDavid et al. 1979; Nade et al. 1983).
TGF-ß
The use of autogenous bone marrow re-
quires a harvesting operation. The amount of
marrow being limited, it would be ideal to
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have a prefabricated, “ off the shelf” bone
substitute with bone induction capacity.
In recent years, transforming growth factor
beta (TGF-ß) has been examined experimen-
tally together with a variety of biomaterials to
induce bone growth. Although promising, the
results must be interpreted with great caution
owing to the complex and multiple effects of
TGF-ß (Beck et al. 1991; Gombotz et al.
1994; Ripamonti et al. 1997; Schmitt et al.
1998).
The data presented in study III demon-
strate that TGF-ß1 applied to natural coral
implant significantly enhanced new bone
growth in the calvarial defect of nongrowing
rats (Figure 13). The bone grew mainly at the
margins of the defect but did not completely
bridge the implant in any of the specimens
during 8 weeks.
Bone formation was the result of "a single
injection" of TGF-ß1 delivered from the NC
implant. Beck and coworkers showed that a
single injection of TGF-ß in 3% methylcellu-
lose triggers a cascade of events leading to new
bone formation in rabbit skull in the course of
49 days (Beck et al. 1991). Apparently TGF-
ß can bind tightly to bone matrix in its active
form, as shown when radioiodinated recombi-
nant human TGF-ß1 in a 3% methylcellulose
vehicle was applied to a skull defect in rabbit.
Sixteen days later, radioactivity was still de-
tected in the defect area where rhTGF-ß1 was
incorporated into the matrix (Richardson et al.
1993). These results show that the effect of
TGF-ß can be prolonged and that it probably
takes place through various mechanisms.
Our findings are in accordance with the
above data. The 5µg and 25µg implants
showed a tendency towards enhanced bone
formation at 3 weeks but the formation was
not statistically significant until at 8 weeks
when compared with the control implants
(Figure 13). The influence of TGF-ß1 on bone
formation may therefore last for several
weeks.
Coral has also been used as a TGF-ß carrier
but, to our knowledge, previous studies were
performed with the granular form of the mate-
rial and the results cannot as such be directly
compared with ours (Damien et al. 1993; Ar-
naud et al. 1994; Boden et al. 1997; Wikesjö et
al. 1998; Arnaud et al. 1999). Arnaud and co-
workers tested 1µg of TGF-ß1 in association
with coral granules and fibrin glue in a CSD
model and obtained significantly better bone
formation with this combination at 2 months
than with TGF-ß1 in methylcellulose or in
fibrin glue alone. Histological sections showed
that bone growth proceeded around the gran-
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ules, not inside them as with solid, porous
coral material (Arnaud et al. 1994).
In our study, bone formation was enhanced
by TGF-ß but was limited mainly to the de-
fect margin area. The rats were 6 months old
and can be considered mature, nongrowing
animals. When porous hydroxyapatite im-
plants were soaked in bone marrow cell sus-
pension and implanted subcutaneously in
young (8-week) and old (60-week) rats, the
bone formation capacity was lower in the aged
rats (Inoue et al. 1997). Similar results have
been obtained in other experiments on old rats
(Quarto et al. 1995). Thus age also seems to
affect the capacity of TGF-ß to stimulate
bone formation and may explain, at least to
some extent, the limited bone ingrowth in the
implants studied here.
We did not observe dose dependence on
bone formation at different concentrations of
TGF-ß1. The optimal dose has not previously
been defined. A single injection of 1µg of
TGF-ß1 into neonatal rat periosteum caused
parietal bone thickening at 12 days but a
200ng dose resulted only in increased forma-
tion of osteoprogenitor cell layers and bone
matrix at the early stage, not after 12 days
(Tanaka et al. 1993). Recently, a much lower
dose, 5 or 25ng, injected under the periosteum
caused woven bone formation in 4-week-old
rats (Fujimoto et al. 1999). However, the
same study showed a decrease in bone forma-
tion when TGF-ß1 was injected into the pe-
riosteum repeatedly. Centrella and coworkers
noted that the effect of TGF-ß on bone cell
replication is biphasic and depends on both
the TGF-ß concentration and the cell density
in monolayer culture (Centrella et al. 1987).
Dose dependence is even more complicated
when TGF-ß is released from a vehicle.
MacKinney and coworkers noted that a 40µg
dose of TGF-ß1 in 3% methylcellulose pro-
moted more bone formation than did 0.4 or
5µg in a rabbit CSD experiment (McKinney
and Hollinger 1996). Earlier, Beck and co-
workers had obtained similar results (Beck et
al. 1993). In a recent rabbit CSD experiment
using bone wax polymer as the carrier, a dose
of 2µg of TGF-ß led to decreased bone forma-
tion at 12 weeks. It was speculated that this
was due to the incomplete biodegradation of
the carrier (Schmitt et al. 1998). Used in con-
junction with TGF-ß1, gelatine sponge has
stimulated very limited bone formation in rat
calvaria (Bosch et al. 1996) at doses of 2, 5
and 10µg. The follow-up time was only 2
weeks and the rats were nongrowing, 6-
month-old animals. In addition, the control
defects were in the same animal, and thus the
TGF-ß may have diffused to the control site.
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These factors may explain the poor results.
Ripamonti and coworkers obtained equally
poor results in primates, and suggested that
the limited bone formation was the result of
TGF-ß's capacity to stimulate the prolifera-
tion of only periosteal and endosteal cells
rather than to initiate bone cell differentiation,
as does bone morphogenetic protein (Ri-
pamonti et al. 1996).
These and other results show that the ef-
fect of TGF-ß on bone formation in animals
depends, not only on the age and species of
the animals, but also on the doses used, the
location of the injection site and the type of
delivery material employed.
Compressive strength
In the compressive strength experiment (II)
we used HA and CC implants treated in the
same manner as in study I. The results (II)
should be related to those obtained in study I
(Figures 8 and 10).
The implanted HA blocks were stronger
than the wet, unimplanted specimens (Table 4
and Figure 11a). The compressive strength
and modulus did not increase after 3 weeks.
At 12 weeks a difference was noted in com-
pressive strength between the HA with mar-
row and the control implants. The amount of
bone in study I at 12 weeks constituted
15.4% of the porous area. It did not increase
significantly after 3 weeks, although there was
an increasing tendency at 24 weeks.
Piecuch and coworkers implanted HA
blocks similar to ours on the edentulous ridge
of dogs for 24 months. The compressive
strength was greater than with dry (not im-
planted) specimens but was not related to the
amount of bone ingrowth (Piecuch et al.
1984). Martin and coworkers implanted po-
rous (porosity 65-75% and pore size 260-600
µm) HA blocks into cortical bone of the ra-
dius and cancellous bone of the humerus in
dogs and noticed nonlinear correlation with
bone ingrowth and compressve strength in the
cortical site. The bone ingrowth (% bone of
the porous space ) increased from 22% at 4
weeks to 74% at 1 year and the increase in
compressive strength and elastic compressive
modulus was significant (Martin et al. 1993).
Ohgushi and coworkers used an intramuscular
rat model similar to that used here and induced
bone formation with marrow into porous (400
µm) implant with 60% hydroxyapatite and
40% tricalcium phosphate. They found that
the compressive strength and rigidity were
already significantly higher at 4 weeks in
blocks with bone formation than in controls
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with only fibrous tissue ingrowth (Ohgushi et
al. 1989).
Data from several sources show that the
exact effect of bone ingrowth on the compres-
sive strength and compressive elastic modulus
of porous implants needs further study. The
mode of tissue ingrowth differs, depending on
whether the implants are placed in soft tissue
or in direct contact with bone. The outcome is
also affected by pore size and porosity (Le
Huec et al. 1995).
The porous material with tissue ingrowth
acts as a composite structure. The implanted
block consists of the mineral matrix of the
block, fibrovascular tissue and bony tissue.
Each component affects on the compressive
strength, but, with CC, resorption makes in-
terpretation very difficult. The matrix resorbs
and softens and the porous structure changes.
The importance of new bone formation is thus
underlined.
If bone ingrowth is insufficient, the effect
of fibrous tissue on the strength becomes im-
portant. In study I, the pores of HA blocks
without marrow were fully filled with fibrous
tissue at 3 weeks. We observed a significant
increase in strength in blocks without bone
marrow when compared with wet blocks. The
elastic compressive modulus did not change
but fibrovascular ingrowth seemed to make
the HA implant stronger, although not as
strong as implants with bone ingrowth.
The material strength and modulus of coral
were high compared with those of HA but
there was a very distinct decrease in strength
at 3 weeks (Figure 10). After the implanta-
tion, the compressive strength and the com-
pressive elastic modulus remained unchanged
between 3 and 6 weeks in the marrow group.
In study I bone occupied 20.1% of the porous
area at 3 weeks in coral implants with mar-
row. In the mechanical test, the 3-week im-
plants were stronger than the controls, which
previously had shown only fibrous tissue in-
growth (Table 5). At 6 weeks, the coral blocks
with marrow had partly resorbed, but the
strength and modulus remained at the same
level. This may be the result of two opposite
reactions: the matrix resorbs slowly but at the
same time the amount of bone related to the
reduced implant size increases. The compres-
sive strength and modulus for coral in our
study were comparable to those of cancellous
bone up to 6 weeks in the marrow group but
were already very low at 3 weeks in controls.
Biodegradation
Well documented HA was chosen as a ref-
erence material for CC because of the similar-
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ity in their structure. The limited resorption
of HA (White and Shors 1986) was confirmed
in our study (I-II). Whereas, the resorption of
coral varied widely (Table 3 and 6). It has
been suggested that the main factor in the re-
sorption process is carbonic anhydrase, an
enzyme abundant in osteoclasts (Guillemin et
al. 1981). The enzyme lowers the pH at the
osteoclast-implant interface, dissolving the
calcium carbonate matrix (Chétail and Fournié
1969). Resorption is most active in the bone-
matrix contact areas and proceeds centripe-
tally (Braye et al. 1996). The same resorption
pattern was noted here (I, III, IV), with or
without the presence of bone tissue.
Resorption through carbonic anhydrase ac-
tivity is not the only, possibly not even the
most important, resorption mechanisms.
There was no bone formation in control im-
plants in study I but the resorption rate was
similar to that in the bone marrow group (Ta-
ble 3). In study II the control implants at 6
weeks could not been tested due to deforma-
tion. Giant cells were found in control im-
plants (I) but we could not determine whether
or not these cells were osteoclasts. In the or-
thotopic site (III), where abundant osteoclasts
are present, the control implants showed re-
sorption at 4 weeks but all the implants re-
mained, albeit deformed, at 8 weeks. One
would expect faster resorption if the carbonic
anhydrase enzyme were the main factor in the
resorption process.
Fricain and coworkers studied mouse
macrophages and human fibroplasts in vitro
and suggested that these cells are capable of
phagosytizing coral. Direct contact between
these cells and the coral matrix is a prerequi-
site for the process (Fricain et al. 1998, a). In
fact, the control implants in study I were al-
ready filled with fibrous tissue at 3 weeks,
which could explain the similarity in the re-
sorption rate to that in the marrow group. The
results of study IV are in accordance with this
observation. One implant placed to the iliac
crest (IV) had no tissue ingrowth at 1 year;
this implant remained the largest block
throughout the follow up period (Figure 16c).
We also studied the histology of the one in-
fected block 1.7 years after implantation, and
found that the coral matrix was completely
preserved in areas without tissue ingrowth
(Figure 16 f). In contrast, the block that re-
sorbed the fastest was fully occupied by bone
and fibrous tissue at 1 year.
In study III the 25µg TGF-ß1 group
showed less resorption at 8 weeks than did
the controls (Figure 14). In general, the struc-
ture of the TGF-ß1-treated implants was
much better preserved than that of the coral
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controls, in which the matrix had partly col-
lapsed (Figure 12A). Diminished resorption of
CC has not previously been reported in con-
junction with TGF-ß.
TGF-ß stimulates fibroblast growth (Leof
et al. 1986; Franzen and Dahlquist 1994) but
deactivates macrophages (Tsunawaki et al.
1988). The number of macrophages in our
TGF-ß1 treated implants was lower than in
our coral controls (Figure 12D). On the other
hand, empty areas without any fibrotic tissue
inside the CC implants could be detected in
the 5 and 25µg 3-week groups, implying pos-
sible inhibition of fibrotic tissue growth (Fig-
ure 12E). We were unable to explain this ap-
parent discrepancy in diminished fibrotic tis-
sue growth and known fibrotic tissue stimula-
tion by TGF-ß. It is nevertheless consistent
with the diminished resorption of CC.
Resorption appears to proceed more rap-
idly in animals than in humans. When CC
blocks were implanted in the cortex of the fe-
mur and tibia in pig and sheep, resorption at 1
month was 64% and 93%, respectively
(Guillemin et al. 1989). Complete resorption
of CC granules has been observed at 24 weeks
in a connective tissue site in pigs (Naaman et
al. 1994). In our experiment in the intramus-
cular site the coral implants were deformed at
6 weeks and one implant was completely re-
sorbed in the control group (I). At 12 weeks
the mean total cross-sectional area was 40%
of the original (Table 3.)
In humans, degradation seems to be slower.
50% of the blocks used to fill the 10mm cra-
nial burr holes resorbed completely at 1 year
(Roux et al. 1988). In spinal fusions small
fragments of natural coral blocks were found
after 1 year (Pouliquen et al. 1989). When
traumatic methaphyseal defects were filled
with coral blocks, resorption times of over 4
years have been reported (de Peretti et al.
1996).
Our experiment showed that CC implants
placed into the iliac crest were less than 50%
of their original size after 2 years. None of the
blocks resorbed completely and one implant
was more than 75% of its original size (Table
6). The resorption is unpredictable and the
mechanisms are not fully understood.
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SUMMARY
The main purpose of this study was to ex-
amine bone ingrowth into hyroxyapatite and
calcium carbonate bone substitutes when bone
ingrowth was induced with bone marrow or
TGF-ß. In addition, special interest focused
on the resorption rate and pattern of CC im-
plants.
A total of 113 rats received 167 HA or CC
implants. CC implants were also placed into
iliac crest defects in 10 humans.
In the first experiment CC and HA blocks
were implanted in rat latissimus dorsi muscle
with autogenous bone marrow to compare
their bone-forming capability. A block with-
out marrow placed in the opposite latissimus
muscle served as a control.
The animals were killed at 3, 6 and 12
weeks and, in the hydroxyapatite group, also
at 24 weeks. The sections were analysed his-
tologically and histomorphometrically.
The second experiment examined the effect
of tissue ingrowth on the compressive
strength of the CC and HA implants. The im-
plants were obtained in a process similar to
that used in the first investigation.
In the third experiment 1µg, 5µg and 25µg
of TGF-ß1 were added to CC blocks that
were placed into a critical size defect in the
parietal bone of rat. The implants were re-
trieved at 3 and 8 weeks and the capacity of
TGF-ß1 to enhance bone formation was ex-
amined by histology and histomorphometry
in undecalcified sections.
In the fourth investigation a bicortical bone
graft was harvested from the iliac crest of 10
patients and the defect was filled with a CC
block. The fate of the implant was monitored
by X-rays and quantitative CT scans for a
mean of 2.1 years. A biopsy was taken at 1
year. Another 10 patients with a similar de-
fect but without any implant served as con-
trols.
Study I showed that bone formation could
be induced into calcium ceramics by bone mar-
row. More bone was found in CC than in HA
implants at 3 weeks (10.8% versus 4.8%) and
at 12 weeks (13.7% versus 6.3%, bone/total
original block area). There was no bone in con-
trol implants.
TGF-ß1 induced significant, but limited,
bone enhancement in the CSD experiment
(III). None of the implants showed bone
bridging over the defect.
In the orthotopic site in humans, at iliac
crest site, only two of seven biopsies showed
bone ingrowth into the implant (IV).
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Bone ingrowth resulted in greater compres-
sive strength in HA implants than in controls
at 12 weeks (II). CC resorbed quickly and lost
its compressive strength, which was originally
higher than in HA. At 3 weeks the marrow
group was stronger than the control CC
specimens. Bone ingrowth seemed to maintain
the strength of the coral implant even if it was
dissolving. The mechanical strength of both
materials was comparable to that of cancellous
bone.
Resorption was not observed in HA im-
plants. The resorption in CC implants was
evident in the intramuscular site at 3 weeks
and was similar in both control and bone mar-
row implants. At 12 weeks the cross-sectional
area of the block had diminished to 40% of the
original area.
Resorption was lower in the TGF-ß1
treated implants (III) than in the control im-
plants. The number of macrophages and giant
cells was reduced in the TGF-ß1 implants,
which showed less resorption and more intact
structure than did the coral controls. Void ar-
eas without any fibrous tissue ingrowth were
found only in the TGF-ß1-treated implants,
which may partly explain the reduced resorp-
tion.
Resorption proceeded centripetally and
apparently more rapidly when accompanied
by tissue ingrowth (I, II, III and IV). None of
the implants placed into the iliac crest re-
sorbed competely during follow-up ( mean 2.1
year).
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CONCLUSIONS
1) Bone marrow induced more bone ingrowth into CC than into HA implants in an intramus-
cular site, even though CC resorbed over time. Bone did not form without bone marrow. Fi-
brovascular and bone tissue already occupied the pores almost completely at 3 weeks.
TGF-ß1 promoted significant, but only limited, bone ingrowth into CC implants in an ortho-
topic site. Bone formation did not depend on the TGF-ß1 dose. The age of the animals may
have contributed to the limited response.
2)  Bone ingrowth into HA enhances its compressive strength. CC dissolves and becomes
weaker even if bone ingrowth seems to maintain the strength to some extent. The compres-
sive strength of both materials is comparable to that of cancellous bone but is not sufficient
for them to be used in weight bearing areas.
3) The resorption of CC varies widely in the intramuscular site. There was no difference be-
tween the control and marrow groups, which suggests that mechanisms other than resorption
by the carbonic anhydrase enzyme may play a more important role in the resorption proc-
ess.
TGF-ß1 diminished the resorption of CC implants, possibly by reducing soft tissue in-
growth and by deactivating macrophages.
In humans the resorption of large CC implants in an orthotopic site proceeds very slowly
and the implant is only partially replaced by bone.
If CC or HA implants are used as bone substitutes, bone formation should be induced either
by bone marrow or, in the future, by a combination of different growth factors.
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